Morgan Stanley set a CHF 260 price target on Roche (VTX:ROG) in a report released on Friday. The brokerage currently has a neutral rating on the healthcare company’s stock.

Other equities research analysts have also recently issued reports about the company. Goldman Sachs Group set a CHF 325 price objective on Roche and gave the company a buy rating in a research report on Thursday, September 21st. Barclays set a CHF 295 target price on Roche and gave the stock a buy rating in a research report on Wednesday, September 13th. Berenberg Bank set a CHF 273 target price on Roche and gave the stock a buy rating in a research report on Tuesday, August 15th. Credit Suisse Group set a CHF 300 target price on Roche and gave the stock a buy rating in a research report on Monday, September 11th. Finally, J P Morgan Chase & Co reaffirmed a buy rating on shares of Roche in a research report on Monday, September 11th. Three investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and eight have assigned a buy rating to the company’s stock. The company has an average rating of Hold and an average price target of CHF 261.32.

Shares of Roche (VTX ROG) opened at CHF 240.50 on Friday. Roche has a 12-month low of CHF 220.50 and a 12-month high of CHF 273.

ILLEGAL ACTIVITY NOTICE: “Morgan Stanley Analysts Give Roche (ROG) a CHF 260 Price Target” was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this piece can be read at https://www.thecerbatgem.com/2017/12/11/morgan-stanley-analysts-give-roche-rog-a-chf-260-price-target.html.

About Roche

Roche Holding AG (Roche) is a research-based healthcare company. The Company’s operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics.

Analyst Recommendations for Roche (VTX:ROG)

Receive News & Stock Ratings for Roche Holding Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche Holding Ltd. and related stocks with our FREE daily email newsletter.